Ventoux Biosciences
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
315 S Coast Hwy 101 Ste U245, Encinitas,...Phone Number
(760) 621-8562Website
www.ventouxbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Ventoux Biosciences
Ventoux Biosciences is focused on developing immune-fibrotic therapies aimed at preserving function and improving outcomes for patients suffering from diseases and injuries, particularly targeting Dupuytrens disease and spinal cord injury. Their lead program, VEN-201, is advancing through preclinical development, utilizing AI-guided, multi-omic analysis to identify novel therapeutic targets. The company aims to provide innovative, non-surgical pharmacologic treatments that address significant unmet medical needs in these conditions. With a strong emphasis on patient insight and a differentiated pipeline, Ventoux is committed to redefining fibrosis through immune modulation.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ventoux Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Ventoux Biosciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if Ventoux Biosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Ventoux Biosciences
Check out if Ventoux Biosciences is spiking on competitors!
Earning: See what the market has to say on Ventoux Biosciences recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Ventoux Biosciences launches new products
Funding: Get notified immidiatlly once Ventoux Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Ventoux Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Ventoux Biosciences
Compare insights from companies similar to Ventoux Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ventoux Biosciences
<$5M
1-10
Private
-
2022
N/A
Company Profile Activity
Activity Insights
Ventoux Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ventoux Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ventoux Biosciences.
Ventoux Biosciences News & Media
Ventoux Biosciences Announces Positive Pre-Clinical Results, Initiates Fundraising Round to Advance Development
Ventoux Biosciences, Founded by Dupuytren's Patient, Announces Positive Anti-Fibrotic Effects with VEN-201 and Initiates Initial Fundraising Round ENCINITAS, CALIFORNIA, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- Ventoux Biosciences …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ventoux Biosciences
Sign Up For FreeTo access detailed company insights
Ventoux Biosciences is focused on developing immune-fibrotic therapies aimed at preserving function and improving outcomes for patients suffering from diseases and injuries, particularly targeting Dupuytrens disease and spinal cord injury. Their lead program, VEN-201, is advancing through preclinical development, utilizing AI-guided, multi-omic ana... Read More
